A Pilot Study of Golidocitinib, a JAK1 Inhibitor, in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia (GEMSTONE)

This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular lymphocytic leukemia (T-LGLL) requiring treatment, n=12. Patients will receive single agent golidocitinib at the previously established dose of 150 mg QD as determined in the phase I and II studies of golidocitinib.

Start Date30 Sep 2026

Sponsor / Collaborator

Washington University School of Medicine

[+1]

NCT07737249

/ Not yet recruitingPhase 2IIT

A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Golidocitinib in Rapidly Progressive Interstitial Lung Disease

The goal of this clinical trial is to learn whether adding the JAK inhibitor golidocitinib to standard corticosteroid therapy works to treat rapidly progressive interstitial lung disease (RP-ILD) in patients with acute worsening. It will also learn about its safety compared to standard treatment without JAK inhibitors (i.e., corticosteroids plus other immunosuppressants such as mycophenolate mofetil, tacrolimus, cyclophosphamide, or biologics).
The main questions it aims to answer are:
* How much does the addition of golidocitinib improve lung function, measured by the absolute change in FVC (mL), after 12 weeks of treatment?
* How does it compare to standard therapy in terms of changes in FVC% predicted, oxygenation index, chest CT score, need for invasive respiratory support, all-cause mortality, relapse rate, and incidence of opportunistic infections?
Researchers will compare the golidocitinib group (golidocitinib 150 mg once daily plus corticosteroids) to the control group (corticosteroids plus non-JAK inhibitor immunosuppressants). All patients receive high-dose corticosteroids (prednisone equivalent ≥1 mg/kg/day) with a tapering regimen.
Participants will:
* Receive either golidocitinib plus corticosteroids or control treatment for 12 weeks
* Visit the clinic for check-ups, blood tests, and lung function tests at weeks 1, 2, 4, 6-8, and 12
* Have chest high-resolution CT scans at weeks 2, 4-6, and 12 to monitor disease progression
* Be monitored for adverse events and efficacy outcomes throughout the 12-week period

Start Date01 Sep 2026

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT07753642

/ Not yet recruitingPhase 2IIT

A Phase II, Prospective, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golidocitinib Combined With an Anthracycline-Based Regimen as First-Line Treatment for Patients With Nodal T-follicular Helper (TFH) Cell Lymphoma

This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with previously untreated nodal T-follicular helper (TFH) cell lymphoma.

Start Date15 Aug 2026

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Golidocitinib

100 Translational Medicine associated with Golidocitinib

100 Patents (Medical) associated with Golidocitinib

259

Literatures (Medical) associated with Golidocitinib

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Filgotinib induces apoptosis in colorectal cancer cells by activating the p53 signaling pathway

Article

Author: Ye, Huiming ; Li, Zhen ; Zhao, Yanyang ; Zhou, Ying ; Li, Chenmeng

BACKGROUND:

Colorectal cancer remains a significant health challenge. Filgotinib is a selective JAK1 inhibitor approved for the treatment of inflammatory diseases. However, its anti-tumor effects and underlying mechanisms in colorectal cancer (CRC) remain unexplored.

METHODS AND RESULTS:

In this study, cell viability and proliferation were assessed by CCK‑8, crystal violet, and EdU assays. Mitochondrial membrane potential was evaluated using JC‑1 staining. Transcriptome sequencing (RNA‑seq) was performed on RKO cells treated with Filgotinib, followed by GO and KEGG pathway enrichment analyses. Protein expression was examined by Western blot. The effect of Filgotinib was further validated in three human CRC patient‑derived organoids (PDOs). Filgotinib at concentrations near the IC₅₀ (14 µM for HCT116, 10 µM for RKO, 14 µM for LoVo) reduced cell viability and proliferation, as shown by CCK‑8, crystal violet, and EdU assays. Western blot analysis confirmed reduced JAK1 and STAT3 protein expression after Filgotinib treatment compared with the control. Filgotinib induced mitochondrial‑dependent apoptosis, evidenced by increased green fluorescence in the JC‑1 assay. Transcriptomic profiling of RKO cells treated with 10 µM Filgotinib for 48 h identified 1,151 upregulated and 862 downregulated genes. GO analysis revealed enrichment in terms related to chromatin structure, nucleotide binding, and metabolic processes. KEGG analysis highlighted activation of the p53 signaling pathway and suppression of oncogenic pathways including VEGF and TNF signaling. At the protein level, Filgotinib treatment increased the expression of p21 (a key p53 pathway effector) and cleaved caspase-3 compared with the control group. Furthermore, treatment of human CRC-derived PDOs with Filgotinib (≥ 10 µM) for 48 h resulted in organoid disintegration.

CONCLUSIONS:

Our study demonstrates that Filgotinib exerts direct anti-tumor effects in CRC by triggering apoptosis, activating the p53 pathway, and inhibiting pro-survival VEGF and TNF pathways. These findings support its potential as a targeted therapeutic agent for CRC.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Selective modulation of IL-6/JAK/STAT-related signaling under redox-shift conditions by luteolin

Article

Author: Aydın, Elif ; Kaymak, Güllü ; Sezgin, Ayşe Koçak ; Gündüz, Meliha Koldemir

BACKGROUND:

Luteolin is a naturally occurring flavone known to modulate cellular redox balance and inflammatory signaling; however, its role in integrated redox-inflammatory responses remains incompletely defined. The present study investigated the effects of luteolin, alone and in combination with the selective JAK1 inhibitor upadacitinib, on oxidative stress parameters, inflammatory mediators, and JAK/STAT-related gene expression in human breast (MCF-7), colorectal (HT-29), and hepatocellular (HepG2) cancer cell lines, with L929 fibroblasts as a non-tumor comparator.

OBJECTIVE:

Real-time impedance analysis was used to establish cytotoxicity profiles and define submaximal, non-lethal exposure conditions. Under these conditions, total oxidant status (TOS), total antioxidant status (TAS), lipid peroxidation (MDA), catalase (CAT) activity, and glutathione (GSH) levels were assessed, together with interleukin-6 (IL-6) and interleukin-1β (IL-1β) secretion and transcriptional expression of JAK1, JAK2, JAK3, and STAT3.

METHODS:

Luteolin exposure was associated with a consistent reduction in oxidative burden (decreased TOS and MDA) and enhancement of antioxidant capacity (increased TAS, CAT, and GSH) across cell lines, indicating a shift toward a more reduced intracellular state. These changes were accompanied by selective modulation of inflammatory signaling, characterized by a reduction in IL-6 secretion in a cell line-dependent manner, while IL-1β levels remained largely unchanged. Transcriptional downregulation of JAK/STAT pathway components was observed following luteolin exposure, with additional modulation in combination with upadacitinib.

RESULTS:

Importantly, these findings reflect transcriptional and biochemical alterations under basal, non-stimulated conditions and do not constitute direct evidence of functional pathway inhibition. Furthermore, the concentrations required to induce these effects exceed typical physiological levels, indicating that the observed responses should be interpreted within a mechanistic in vitro framework.

CONCLUSION:

Collectively, the results demonstrate that luteolin induces a redox shift associated with selective modulation of IL-6-related signaling without broad cytokine suppression. These findings support the use of luteolin as a context-dependent redox modulator and a tool compound for investigating redox-inflammatory pathway interactions in vitro.

01 Sep 2026·AUTOIMMUNITY REVIEWS

Unraveling giant cell arteritis: From immunopathology to emerging targeted therapies (2026 update)

Review

Author: Parreau, Simon ; Ly, Kim ; Gallet, Francois ; Cayrou, Cory ; Bouanat, Sacha ; Fauchais, Anne-Laure

Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly mainly because of cellular senescence and "inflammaging" It results from granulomatous inflammation primarily affecting the aorta and its major branches. Recent advances highlight vascular dendritic cell (DC) activation via TLRs as the initiating event, leading to chemokine-mediated recruitment and polarization of CD4+ T cells mainly into Th1/Th17 subsets. These effector T cells drive monocyte differentiation into pro-inflammatory macrophages and giant cell formation, with subsequent matrix metalloproteinase production causing elastic lamina destruction and vascular remodeling. This vascular remodeling involves activation of endothelial cells, fibroblasts and smooth muscle cells followed by a differentiation in myofibroblast in the intima. Neutrophils may play an underestimated role. Current treatments remain limited to glucocorticoids, methotrexate and tocilizumab though relapse rates remain high. This narrative review synthesizes the DC-T-macrophage-fibroblast cascade and evaluates emerging biologics: abatacept showed phase 2 efficacy but real-world inferiority to tocilizumab; ustekinumab yielded conflicting results across small series; secukinumab failed phase 3 despite promising phase 2 data; anakinra lacked benefit in a truncated trial. In contrast, Mavrilimumab, an anti-GM-CSF-R, is showing promising results. JAK inhibitors such as upadacitinib (a JAK1 inhibitor; SELECT-GCA phase 3) are also promising, having demonstrated superior sustained remission compared with placebo, leading to regulatory approvals in 2025. These findings underscore opportunities to target upstream DC activation, macrophage polarization, and vascular remodeling pathways, potentially transforming GCA management beyond IL-6 inhibition.

101

News (Medical) associated with Golidocitinib

29 Jul 2026

·www.fiercepharma.com

Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026

A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach blockbuster land ahead of schedule. Thanks to a settlement with the Centers for Medicare & Medicaid Services on the classification of Opzelura, Incyte raised its full-year 2026 sales guidance for Opzelura to between $1.05 billion and $1.1 billion, compared to below $800 million in its previous projections. The raise comes after the topical eczema and vitiligo treatment’s second-quarter sales enjoyed a one-time, $246 million boost stemming from the Medicaid rebate settlement. While total sales reached $450 million, the underlying sales of $204 million marked a 24% increase year on year. The June settlement saw CMS agree not to label Opzelura as a line extension of its oral myelofibrosis sister med, Jakafi, when determining its rebate. Incyte expects this to deliver an additional benefit of $40 million to $50 million for the rest of the year. Despite the positive development, Incyte CEO Bill Meury cautioned that the overall market remains in fluctuation. “We continue to view the pricing and reimbursement environment as dynamic, so maintaining broad access and a disciplined gross-to-net profile remains a priority,” he said on Incyte’s July 28 earnings call. A boon from reimbursement did not outshine the underlying expansion of Opzelura, either. In the U.S., Meury highlighted a 26% gain in prescription volume year over year, as Opzelura captured 46% of new-to-brand share among branded topical treatments. Outside the U.S., Opzelura sales reached $43 million in the second quarter, up 34% year over year. The momentum is expected to accelerate as the European Commission just approved Opzelura to treat moderate atopic dermatitis in patients for whom topical corticosteroids and calcineurin inhibitors don’t work. Incyte continues to see long-term growth potential for Opzelura in the international market that could reach two to three times where it is today, Meury said. In another potential catalyst, Incyte expects a phase 3 readout this year for Opzelura in mild to moderate hidradenitis suppurativa, an inflammatory skin condition that causes painful, boil-like lumps. If successful, Opzelura could be the first topical therapy specifically indicated for HS. Meanwhile, Incyte’s bread and butter, Jakafi, enjoyed 7% sales growth compared to the same period last year, hitting $817 million. The FDA recently approved Jakafi XR, the extended-release version of the JAK inhibitor that can be taken once daily rather than the standard twice-daily regimen. The new formulation contributed $10 million to overall Jakafi sales in the second quarter, as the company expects the drug to approach $40 million to $50 million for the full year, according to Meury. The company is on track to achieve its formulary coverage goal of 50% to 70% by year-end, with recent deals with several major payers, including CVS Health and Optum, the CEO said. Incyte’s goal is to convert about 10% or 30% of existing patients to the extended-release formulation before Jakafi’s loss of exclusivity between late 2028 and early 2029. With the sales guidance, the company is targeting a conversion rate between 3% and 5%, Mohamed Issa, head of U.S. commercial, said on Tuesday’s call. RELATED: Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda As the Jakafi patent cliff draws near, investors are increasingly focused on Incyte’s pipeline. The company’s next-generation, selective JAK1 inhibitor povorcitinib is under FDA review for HS, as Incyte expects a U.S. approval in the first quarter of 2027. The company attributed a 6% increase in expenses in the second quarter to pre-launch preparations for povorcitinib. The drug recently turned up some positive data in vitiligo and is on track to report pivotal results for prurigo nodularis this year. During the quarter, Incyte also nixed a JAK2 inhibitor candidate, called INCB160058, to focus on other JAK2V617F-targeted programs in its pipeline.

Drug ApprovalPhase 3

27 Jul 2026

·www.fiercebiotech.com

AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates

AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates (ADCs) despite scrapping two candidates that underperformed in the clinic. They included an EGFR-cMET TOP1i ADC called tilatamig samrotecan that was being evaluated in a phase 1 study of 403 patients with advanced solid tumors like non-small cell lung cancer, head and neck squamous-cell carcinoma and colorectal cancer. The trial kicked off in early 2023, but AstraZeneca disclosed in its second-quarter earnings documents that the company has now discontinued the study due to unimpressive pharmacokinetics and pharmacodynamics. AstraZeneca removed tilatamig samrotecan, which had made it into phase 2 development, from its pipeline alongside another in-house ADC dubbed AZD4360. The CLDN18.2 TOP1i ADC was undergoing a phase 1 study in 117 patients with advanced or metastatic Claudin 18.2-expressing pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancer or biliary tract cancer. This study had launched in the second quarter of 2025, according to AstraZeneca’s earnings documents, but has now been terminated “due to efficacy.” AstraZeneca is a major player in the ADC space thanks to the blockbuster Enhertu, and its follow-up Datroway, both of which emerged from a collaboration with Daiichi Sankyo. But executives told Fierce last year that a key focus of the company’s strategy involves “a conscious effort to invest significantly” in its internal pipeline. This has led AstraZeneca to develop its own linker payload and surface marker library, so it has multiple options to combine the right targets with the right warheads. These in-house efforts include a FRα-targeted ADC called torvutatug samrotecan and a B7-H4-directed ADC called puxitatug samrotecan, which are both in phase 3 development. On an earnings call with journalists this morning, AstraZeneca Chief Financial Officer Aradhana Sarin pointed out that the company has “half a dozen plus ADCs which are homegrown, which are in the clinic.” “We are very confident in that,” Sarin told Fierce. Meanwhile, AstraZeneca CEO Pascal Soriot used the scrapped ADCs as an example of why it’s “very important … to fail fast in the early phase.” “That's what we try to do,” Soriot told Fierce on the call. “When we are positive, we move into phase quickly. But we want to fail fast so we can redeploy resources to other projects.” There was better news for AstraZeneca’s in-licensed ADCs this morning, with the company announcing that sonesitatug vedotin, a therapy licensed from KYM that’s also known as sone-ve, had hit the key goals of a phase 3 gastric cancer study. The trial met the dual primary endpoints of overall survival in third and later-line treatment and progression-free survival in Claudin 18.2-positive advanced gastric cancers. But there was a negative note to the results as for the other dual primary endpoint of progression free survival (PFS), as assessed by blinded independent central review, "results showed a trend toward improved PFS in patients treated in the 2nd and later-line setting but did not reach statistical significance," AZ said. Susan Galbraith, Ph.D., the pharma’s head of oncology hematology R&D, was positive in the release, saying that sono-ve “has the potential to reshape the treatment of gastric cancer by replacing classic chemotherapy with this novel targeted antibody drug conjugate to improve outcomes for patients.” “These transformative results from the first phase 3 readout for sone-ve, together with our broad development programme, highlight the potential for sone-ve to become an important new medicine in CLDN18.2-positive cancers,” Galbraith added. AstraZeneca disclosed a couple other changes further back in its pipeline this morning. They included calling time on an inhaled JAK1 inhibitor that was being assessed in a pair of phase 2 studies for asthma. AstraZeneca confirmed this morning that both trials had been discontinued due to efficacy. The final drug in the pharma’s second-quarter clearout was AZD2068, a EGFR/cMET actinium radioconjugate that was being evaluated in a phase 1 study of 110 patients with solid tumors. AstraZeneca said it had ended the program due to disappointing pharmacokinetics and pharmacodynamics.

Phase 1Phase 3ADCClinical ResultPhase 2

15 Jul 2026

·www.prnewswire.com

Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis

HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the Phase III clinical trial evaluating its core product zemprocitinib capsules for the treatment of active ankylosing spondylitis (AS). The successful completion of enrollment marks an important milestone in the development of zemprocitinib for ankylosing spondylitis and brings the program one step closer to providing a new oral treatment option for patients with this chronic inflammatory disease. Study Design and Progress The Phase III study is a randomized, double-blind, placebo-controlled, multicenter clinical trial designed to evaluate the efficacy and safety of zemprocitinib in patients with active ankylosing spondylitis. The primary endpoint is the proportion of patients achieving an Assessment of SpondyloArthritis international Society 40% response (ASAS40) at Week 16. A total of 352 patients have now been enrolled, and the study is proceeding as planned with ongoing treatment, follow-up, and data collection. Ankylosing spondylitis is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and impaired physical function, significantly affecting patients' quality of life. Despite available therapies such as nonsteroidal anti-inflammatory drugs and biologics, a substantial proportion of patients fail to achieve adequate disease control or have concerns regarding long-term treatment safety, leaving significant unmet medical needs. Differentiated Profile of Zemprocitinib Zemprocitinib is a second-generation selective JAK1 inhibitor with the potential to become a best-in-class therapy. Compared with first-generation JAK inhibitors with lower selectivity, zemprocitinib's higher selectivity for JAK1 has the potential to maintain efficacy while reducing safety risks associated with off-target inhibition. Preclinical and clinical studies have shown that zemprocitinib potently and dose-dependently inhibits multiple JAK1-related inflammatory signaling pathways, supporting its therapeutic potential across multiple indications. Previously reported 24-week Phase III data in rheumatoid arthritis and 52-week Phase III data in atopic dermatitis demonstrated that zemprocitinib achieved the primary and key secondary endpoints, while showing rapid and sustained efficacy together with a favorable safety and tolerability profile. Rates of serious adverse events and adverse events of special interest (AESIs) were comparable to placebo, and laboratory safety parameters were also favorable. Dr. Henry Wu, who is responsible for overseeing and directing the overall clinical research program, said: "Based on the encouraging efficacy and favorable safety profile demonstrated by zemprocitinib in Phase III studies in rheumatoid arthritis and atopic dermatitis, we look forward to further evaluating its efficacy and safety in patients with ankylosing spondylitis and generating robust clinical evidence to support subsequent regulatory submissions." Dr. Zhao-Kui (ZK) Wan, Founder, Chairman and Chief Executive Officer of Lynk Pharmaceuticals, said: "The completion of patient enrollment in the Phase III study for ankylosing spondylitis represents another important milestone in the development of zemprocitinib. We look forward to further validating the clinical value of zemprocitinib in this indication and quickly bringing a safer and more effective oral treatment option to patients." About Lynk Pharmaceuticals Lynk Pharmaceuticals is a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, committed to addressing unmet clinical needs through first-in-class innovation, developing differentiated small-molecule therapies, and providing superior oral alternatives to biologics. The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation. The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentiated therapies for patients worldwide. To date, Lynk Pharmaceuticals has successfully developed and progressed multiple Class 1 new drug candidates and advanced multiple pipeline programs through internal research and development as well as global partnerships. Forward-Looking Statements This press release contains certain forward-looking statements. These statements relate to future events and may include, but are not limited to, expectations, plans, or objectives regarding the Company's future research and development programs, business development, collaboration arrangements, and other future matters. Because future events are subject to numerous uncertainties, these forward-looking statements are based on the Company's management's current information, views, assumptions, estimates, and judgments at the time such statements are made. They do not constitute guarantees of future performance, development, or results. Actual events, outcomes, or developments may differ materially from those expressed or implied by such forward-looking statements. Except as required by applicable laws and regulations, the Company undertakes no obligation to update, revise, or supplement any forward-looking statements contained in this press release as a result of future developments or changes in circumstances, nor does the Company assume any responsibility for the failure of any forward-looking statements to materialize or for any differences between such statements and actual results. SOURCE Lynk Pharmaceuticals Co., Ltd. 21% more press release views with Request a Demo

Phase 3Clinical Result

100 Deals associated with Golidocitinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	China	Dizal Pharmaceutical Co., Ltd.	18 Jun 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Large Granular Lymphocytic Leukemia	Phase 2	United States	Dizal Pharmaceutical Co., Ltd.	30 Sep 2026
Mycosis Fungoides	Phase 2	United States	Dizal Pharmaceutical Co., Ltd.	30 Sep 2026
Extensive stage Small Cell Lung Cancer	Phase 2	China	Dizal Pharmaceutical Co., Ltd.	31 Oct 2025
Lymphohistiocytosis, Hemophagocytic	Phase 2	China	Dizhe (Shanghai) Pharmaceutical Co., Ltd.	20 May 2025
PD-L1 positive Non-Small Cell Lung Cancer	Phase 2	China	Dizal Pharmaceutical Co., Ltd.	01 Jan 2024
T-cell lymphoma recurrent	Phase 2	China	Dizal Pharmaceutical Co., Ltd.	31 May 2022
Sezary Syndrome	Phase 2	China	Dizal Pharmaceutical Co., Ltd.	23 Dec 2021
EGFR-mutated non-small Cell Lung Cancer	Phase 2	Australia	Dizal Pharmaceutical Co., Ltd.	16 Apr 2018
Crohn Disease	Preclinical	China	Dizal Pharmaceutical Co., Ltd.	-
Non-Small Cell Lung Cancer	Preclinical	United Kingdom	AstraZeneca PLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06198907 (JACKPOT33, ASCO2026)	Phase 2	PD-L1 positive Lung Cancer First line PD-L1 positive	47	Golidocitinib 150 mg + Sintilimab 200 mg	krigexmute(yusudtfsxr) = ykiepptxxa maghnvhfkl (gewkiunjqg )	Positive	29 May 2026
NCT06198907 (JACKPOT33, ASCO2026)	Phase 2	PD-L1 positive Lung Cancer First line PD-L1 positive	47	Golidocitinib 150 mg + Sintilimab 200 mg (PD-L1 high (TPS ≥50%))	krigexmute(yusudtfsxr) = otagewzvwu maghnvhfkl (gewkiunjqg )	Positive	29 May 2026
EHA2026	Not Applicable	Peripheral T-Cell Lymphoma First line	21	Golidocitinib plus CHOP-like chemotherapy	widvorimls(sqanpqyhkl) = ggvqfmahlb beswgmsrsk (dmtcwpytkb ) View more	Positive	12 May 2026
NCT07339345 (JACKPOT11, EHA2026)	Phase 2	Lymphohistiocytosis, Hemophagocytic	9	Golidocitinib 150 mg	dcvwlelpbw(rndzdxxqfn) = xwgjpdedaz vxyuocyjvz (shufclajfp )	Positive	12 May 2026
EHA2026	Not Applicable	Immunoblastic Lymphadenopathy TET2 \| RHOA \| DNMT3A ... View more	9	MINE regimen + targeted agents	aifnmnfqht(lqvbtqlzbw) = wdhwptbgch exgimwmznf (amwsgeysoj ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Peripheral T-Cell Lymphoma \| Peripheral T-cell lymphoma unspecified refractory	23	Golidocitinib + Liposomal Mitoxantrone	rlmxxzvgqk(jikcojmoqs) = Grade ≥3 neutropenia occurred in 56.5% of patients, and Grade ≥3 thrombocytopenia in 47.8%. Pulmonary infection was reported in 56.5% of patients (including 3 patients with pre-existing infection prior to treatment), and CMV reactivation occurred in 30.4% of patients, all of which resolved with supportive care. kdeeqogmvo (miwhckrlzc ) View more	Positive	12 May 2026
EHA2026	Not Applicable		23	Golidocitinib + Liposomal Mitoxantrone (NKTCL)		Positive	12 May 2026
EHA2026	Not Applicable	Peripheral T-Cell Lymphoma	25	Golidocitinib-containing regimens	fbpguopchk(awjtickhnm) = two patients developed Pneumocystis jirovecii pneumonia (PJP) despite standard prophylaxis jaaoqcxbcz (sekrhnvyer ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Peripheral T-Cell Lymphoma	25	Golidocitinib-containing regimens (HLH)		Positive	12 May 2026
NCT07081607 (EHA2026)	Phase 1/2	Peripheral T-Cell Lymphoma	11	Golidocitinib + Azacitidine + Chidamide	tgcdiskjni(owoyzqxmld) = osbuauxxfb bigvemoepb (ylcpbjzvks ) View more	Positive	12 May 2026
NCT04105010 (JACKPOT8 part B, ASH2025)	Phase 2	Peripheral T-Cell Lymphoma	13	Golidocitinib 150 mg	prbrreufhw(tevscotyxz) = curvqkjlyg fjdklpakfv (fwfllawbyd, 44.2 - 91.9) View more	Positive	06 Dec 2025
NCT06739265 (ASH2025)	Phase 1/2	Peripheral T-Cell Lymphoma First line	18	Golidocitinib + CHOP	camgbkdqaq(lzgbamovcf) = CMV reactivation was observed in 3 patients (16.6%) and warrants close monitoring yogiozhalo (siswikzccp ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	-	16	Golidocitinib monotherapy	xoxzzzblvr(cekzkmatxu) = 28.6% dyoacqezsd (qeufahcnvv ) View more	Positive	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis